Endometrial Endometrioid Adenocarcinoma

Observed

→ investigated in trials for

Carboplatinsmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Letrozolesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Megestrolsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abemaciclibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Anastrozolesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Copanlisibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dordavipronesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dostarlimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enzalutamidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Exemestanesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipatasertibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Metforminsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegfilgrastimother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ribociclibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ruxolitinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tazemetostatsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Thalidomidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Endometrial Endometrioid Adenocarcinoma studied in …STUDIED_INderived10 of 42show all (up to 200)
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 42 trials mapped (24 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07078838Phase 2 · not yet recruiting Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer · condition mapped ALIAS · 42 trials mapped (24 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04604613active not recruiting Prediction of Recurrence Among Low Risk Endometrial Cancer Patients · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02397083Phase 2 · active not recruiting Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07812636early Phase 1 · not yet recruiting Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer · condition mapped ALIAS · 42 trials mapped (24 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 42 trials mapped (24 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07349641Phase 2 · not yet recruiting A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →

Endometrial Endometrioid Adenocarcinoma studied in …STUDIED_INderived10 of 42show all (up to 200)

→ studied in

NCT03348631Phase 2 · active not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 42 trials mapped (24 active)

—

Observed

→ studied in

NCT05256225Phase 3 · recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)

—

Observed

→ studied in

NCT05112601Phase 2 · recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)

—

Observed

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

→ studied in

NCT07078838Phase 2 · not yet recruiting

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer · condition mapped ALIAS · 42 trials mapped (24 active)

—

Observed

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

→ studied in

NCT04604613active not recruiting

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)

—

Observed

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

→ studied in

NCT02397083Phase 2 · active not recruiting

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)

—

Observed

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

→ studied in

NCT07812636early Phase 1 · not yet recruiting

Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer · condition mapped ALIAS · 42 trials mapped (24 active)

—

Observed

→ studied in

NCT05950464Phase 1 · recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 42 trials mapped (24 active)

—

Observed

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

→ studied in

NCT07349641Phase 2 · not yet recruiting

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)

—

Observed

→ studied in

NCT03914612Phase 3 · active not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (24 active)

—

Observed